Phase 4
N=200
Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections
Staphylococcal Infection · Abscess · Staphylococcal Skin Infection · Folliculitis
Bottom Line
View on ClinicalTrials.gov: NCT00352612 ↗Enrolled (actual)
200
Serious AEs
0.0%
Results posted
May 2013
Primary outcome: Primary: Clinical Improvement at the 48-72 Hour Clinical Follow-up — 94; 97 participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- clindamycin (Drug); cephalexin (Drug)
- Age
- Pediatric, Adult · 0+ yrs
- Sex
- All
- Sponsor
- Aaron Chen
- Primary completion
- May 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Clinical Improvement at the 48-72 Hour Clinical Follow-up |
94; 97 | — |
Summary
The purpose of this study is to help define the role of antibiotics in the treatment of pediatric skin infections caused by community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). The investigators hypothesize that treatment with cephalexin, a penicillin-like antibiotic to which CA-MRSA would be expected to be resistant, does not result in poorer outcomes than treatment with clindamycin, an antibiotic to which CA-MRSA is most often susceptible.
Eligibility Criteria
Inclusion Criteria
- Children between the ages of 6 months and 18 years of age (inclusive)
- Suspected purulent staphylococcal skin or soft tissue infection
- No hospitalization within the previous 14 days
- Must have reliable means of follow-up contact (e.g. working phone)
- Outpatient management in the judgement of treating physician
Exclusion Criteria
- Hospitalization on initial visit
- Voluntary withdrawal by the treating physician in order to dictate the antibiotic being used
- Patients with a history of hypersensitivity to or intolerance of cephalexin (or other beta lactams) or clindamycin.
- Patients with altered immunity (inherited or acquired)
- Patients with skin infections related to surgical wounds or hardware.
- Patients currently on antibiotic therapy
Data sourced from ClinicalTrials.gov (NCT00352612). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.